- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 3/06 - Antihyperlipidemics
Patent holdings for IPC class A61P 3/06
Total number of patents in this class: 4664
10-year publication summary
|
134
|
140
|
201
|
271
|
261
|
295
|
276
|
287
|
277
|
270
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Kowa Company, Ltd. | 1209 |
67 |
| Daiichi Sankyo Company, Limited | 1877 |
48 |
| Shionogi & Co., Ltd. | 835 |
48 |
| Amgen Inc. | 4258 |
42 |
| Amarin Pharmaceuticals Ireland Limited | 272 |
42 |
| Takeda Pharmaceutical Company Limited | 2717 |
38 |
| Regeneron Pharmaceuticals, Inc. | 4444 |
38 |
| Janssen Pharmaceutica N.V. | 3351 |
37 |
| Mochida Pharmaceutical Co., Ltd. | 336 |
28 |
| Boehringer Ingelheim International GmbH | 4635 |
27 |
| Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 842 |
27 |
| Novartis AG | 10623 |
25 |
| F. Hoffmann-La Roche AG | 7933 |
25 |
| Albireo AB | 174 |
24 |
| Sunshine Lake Pharma Co., Ltd. | 600 |
24 |
| Bristol-myers Squibb Company | 4820 |
23 |
| Eli Lilly and Company | 3925 |
23 |
| Alnylam Pharmaceuticals, Inc. | 1139 |
22 |
| AstraZeneca AB | 2858 |
20 |
| Suzhou Ribo Life Science Co., Ltd. | 122 |
20 |
| Other owners | 4016 |